Kevin Kalinsky, MD, MS | Authors

Kevin Kalinsky, MD, MS, Discusses Future Analyses of Ribociclib in HR+/HER2– Advanced Breast Cancer

October 10, 2022

Kevin Kalinsky, MD, MS, spoke about future studies following results from the phase 2 MAINTAIN trial of ribociclib with or without endocrine therapy and after progression on a CDK4/6 inhibitor for patients with unresectable or metastatic hormone receptor–positive, HER2-negative breast cancer.

Informed Decision-Making in HR+ Breast Cancer

May 22, 2021

Kevin Kalinsky, MD, MS, of Emory Winship Cancer Institute, discusses treatment options for HR-positive/HER2-negative breast cancer and comments on the evolving role of genomic testing in regard to treatment selection.